Stemedica Cell Technologies
Stemedica Cell Technologies is a clinical-stage biopharmaceutical company specializing in the development and commercialization of progenitor cell and protein therapeutics for medical conditions with limited treatment options.
Company Overview
Stemedica Cell Technologies is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of progenitor cell and protein therapeutics. The company aims to address underserved medical conditions through its advanced therapeutic solutions. Stemedica's core innovation lies in its proprietary manufacturing technology platform that produces allogeneic progenitor cell products in a low-oxygen, low-tension environment. This process ensures high therapeutic efficacy and protection under a cGMP-compliant manufacturing setting.
Lead Drug Candidates
Stemedica Cell Technologies has developed two leading drug candidates: ischemia-tolerant mesenchymal stem cells (itMSCs) and ischemia-tolerant neural progenitor cells (itNSCs). The itMSCs are currently in clinical development, targeting ischemic stroke and Alzheimer's disease. The itNSCs, on the other hand, are being developed to treat spinal cord injuries. Both therapies utilize allogeneic progenitor cells designed to enhance ischemia tolerance and therapeutic efficacy. These candidates are manufactured in Stemedica's cGMP-compliant facility in San Diego.
Manufacturing Capabilities
Stemedica Cell Technologies operates a cGMP-compliant manufacturing facility in San Diego, California. This facility is licensed by the California State Department of Public Health Food and Drug Branch (FDB) to produce cells for use in human clinical trials. The company's proprietary manufacturing technology creates allogeneic progenitor cell products in a hypoxic environment. This unique process enhances the ischemia tolerance, immune privilege, and therapeutic efficacy of the cells. The facility also supports the production of cells for use in FDA-approved clinical trials and supplies progenitor cells to geographic distributors for internationally approved clinical trials and research.
Research and Development
Stemedica Cell Technologies focuses on developing next-generation therapies for critical medical conditions. Currently, the company is advancing its progenitor multi-cell therapy, combining itMSCs and itNSCs, specifically for ischemic stroke and Alzheimer’s disease. Stemedica also works on progenitor cell and protein combination therapy aimed at treating Alzheimer’s disease. Through its R&D efforts, the company seeks to provide innovative treatments to improve patient outcomes and address unmet medical needs.
Intellectual Property and Distribution
Stemedica maintains a robust patent portfolio with various issued patents and pending applications in the United States Patent and Trademark Office. This intellectual property protection supports the company's pioneering work in progenitor cell therapy. Additionally, Stemedica collaborates with exclusive distribution partner ThermoFisher Scientific to supply progenitor cells for international research and clinical trials. The company's cells are utilized globally, complying with regulatory standards set by international agencies.